Condition
Erythromelalgia
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 4 (1)
Trial Status
Completed2
Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04039633Not ApplicableRecruitingPrimary
Spinal Cord Stimulation for Refractory Pain in Erythromelalgia
NCT05917912Phase 2CompletedPrimary
EASE (Efficacy of ATX01 Study in Erythromelalgia)
NCT02696746UnknownPrimary
Painful Channelopathies Study
NCT02214615Phase 4CompletedPrimary
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations
Showing all 4 trials